Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β1

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 133-140

  Ji, Mei ^a   Shi, Huirong ^a   Xie, Ya ^a   Zhao, Zhao ^a   Li, Shunshuang ^a   Chang, Cheng ^a   Cheng, Xinghan ^a   Li, Yue ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cell cycle; Ovarian carcinoma; Transforming growth factor 1; Tumor growth; USP22

Indexed keywords

CYCLIN D2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEUBIQUITINASE; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG; TGFB1 PROTEIN, HUMAN; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME; UPREGULATION; USP22 GENE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; FOLLOW UP; GENE EXPRESSION; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; THIOLESTER HYDROLASES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN;

EID: 84916199429     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3580     Document Type: Article

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Trimbos JB, Vergote I, Bolis G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113-125, 2003.
4. Kurman RJ and Shih IeM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42: 918-931, 2011.
5. Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C and Matei D: Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer 116: 5251-5260, 2010.
6. Lin Z, Yang H, Kong Q, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46: 484-494, 2012.
7. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 62: 229-235, 2012.
8. Zhang XY, Varthi M, Sykes SM, et al: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29: 102-111, 2008.
9. Hu J, Liu YL, Piao SL, Yang DD, Yang YM and Cai L: Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer 77: 593-599, 2012.
10. Piao S, Liu Y, Hu J, et al: USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS One 7: e42540, 2012.
11. Zhang Y, Yao L, Zhang X, et al: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 137: 1245-1253, 2011.
12. Piao S, Ma J, Wang W, et al: Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol 49: 796-801, 2013.
13. Yang DD, Cui BB, Sun LY, et al: The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 61: 703-710, 2011.
14. Xu H, Liu YL, Yang YM and Dong XS: Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis 27: 21-30, 2012.
15. Tian M and Schiemann WP: The TGF-β paradox in human cancer: an update. Future Oncol 5: 259-271, 2009.
16. Bierie B and Moses HL: Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006.
17. Wenner CE and Yan S: Biphasic role of TGF-β1 in signal transduction and crosstalk. J Cell Physiol 196: 42-50, 2003.
18. Principe DR, Doll JA, Bauer J, et al: TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 106: djt369, 2014.
19. Cho MS, Bottsford-Miller J, Vasquez HG, et al: Platelets increase the proliferation of ovarian cancer cells. Blood 120: 4869-4872, 2012.
20. Cai J, Tang H, Xu L, et al: Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 33: 20-29, 2012.
21. Yang Y, Kitagaki J, Wang H, Hou DX and Perantoni AO: Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 100: 24-28, 2009.
22. Song L and Rape M: Reverse the curse-the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 20: 156-163, 2008.
23. Shen M, Schmitt S, Buac D and Dou QP: Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 17: 1091-1108, 2013.
24. Hussain S, Zhang Y and Galardy PJ: DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 8: 1688-1697, 2009.
25. Kapoor S: Usp22 and its evolving role in systemic carcinogenesis. Lung Cancer 79: 191, 2013.
26. Schrecengost RS, Dean JL, Goodwin JF, et al: USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res 74: 272-286, 2014.
27. Liu YL, Yang YM, Xu H and Dong XS: Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 25: 1800-1805, 2010.
28. Li J, Wang Z and Li Y: USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138: 1291-1297, 2012.
29. Kajdaniuk D, Marek B, Borgiel-Marek H and Kos-Kudla B: Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol 64: 384-396, 2013.
30. Moses H and Barcellos-Hoff MH: TGF-β biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol 3: a003277, 2011.
31. Anscher MS: Targeting the TGF-β1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 15: 350-359, 2010.
32. Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ and Jiang GS: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 346: 11-21, 2011.